Molecular Cancer Therapeutics Impact Factor, Indexing, Ranking

Molecular Cancer Therapeutics (MCr) is a scholarly journal dedicated to publishing research in the field of Medicine. American Association for Cancer Research is the publisher of this esteemed journal. The P-ISSN assigned to Molecular Cancer Therapeutics is 1535-7163 and its abbreviated form is Mol Cancer Ther.

Molecular Cancer Therapeutics publishes translational research studies focused on the discovery and preclinical development of therapeutic agents for oncology. To reflect the evolving field of therapeutics, the journal’s interest extends to all selective drugs including small molecule inhibitors, antibody-drug conjugates, antibody cytokine fusions, bispecific antibodies, cell therapies, gene therapies, radio-immunotherapeutics, vaccines, viral therapies, and other experimental approaches in oncology.

Specific areas of interest are the disclosure of translational investigations of novel drug therapies, preclinical studies of approved therapeutics (including their combination with radiation therapy), mechanisms of action, mitigation of resistance, biomarkers of response, novel models and technology, and applications of big data in drug discovery.

The following guidelines, which may be revised from time to time, describe what the Editors are looking for in submitted manuscripts:

• Data/experiments are substantive and support conclusions; all key experiments are designed and performed properly.
• Sufficient detail is provided to facilitate repetition of the experiments to verify data.
• Rigorous statistical evaluation is performed. Sufficient group size is used for animal studies.
• Appropriate replicates in cellular studies are used.
• Relevant cell lines, animal models, and assays are utilized.
• Studies must be performed according to AACR and Institutional Guidelines.
• Multiple relevant cell lines (or patient specimens) are examined/used/studied to support conclusions.
• Studies are performed using relevant concentrations of agents, conditions, schedules, and other related material. Where human data exists, the data should be used to define parameters for laboratory studies.
• Appropriate controls are employed for all experiments (especially inactive analog compounds).
• In vivo studies should go beyond establishment of biological effect and show modulation of the intended target (or cellular pathway) in vivo. Pharmacokinetic (PK)/pharmacodynamics (PD) studies are extremely useful; dose-response should be demonstrated.
• Inclusion of relevant structures of compounds mentioned or used in the work is essential and enhances the readability of the paper. Studies with uncharacterized mixture of Natural Products will not be considered.
• For novel structures previously unreported, experimental details of synthesis should be included in the main body of the paper or in Supplementary Material.
• Any references or patents cited that provide the synthesis of compounds should be specific, not general, and should be easily obtained.

Abbreviation : ISO Journal abbreviation refers to the shortened form or acronym used to represent the full title of a scholarly journal. The ISO4 Abbreviation of Molecular Cancer Therapeutics Journal is Mol Cancer Ther.

The Ranking of the Journal in 2024 is 1449. Ranking systems aim to provide an indication of a journal's quality, influence, and prestige within a specific field or discipline.

The Journal's Impact Factor in 2024 is 5.7. it is all calculated by Clarivate, which means how many times a particular citation has been published in the past two years.

List of All Journal Impact Factors

The Journal SCImago in 2024 is 1.890. It is measured by the number of citations which are made by the particular journals, and the journal from where the citations arrived from.

The Journal's H-Index in 2024 is 190. The H-index is calculated on how many times a particular author is cited and the number of published papers that a particular author has.

The Journal's Quartile is Q1. A quartile has three points, which are the upper quartile, median, and lower quartile. The main motive of the quartile is to calculate the interquartile range, that resembles the changes across the median.

The Journal is indexed in (Indexing details)

• 1. Web of Science
• 2. UGC
• 3. Scopus
• 4. PubMed
• 5. ProQuest
• 6. Medline
• 7. Google Scholar
• 8. BIOSIS Previews

Indexing services aim to make it easier for researchers, scholars, and readers to discover and access articles from various journals within a specific field or discipline.

The Editor-in-chief of the Journal is Beverly A Teicher

Processing/Submission Fee : Article submission/Processing fees (APC), also known as manuscript Publication fees or processing fees (APC), are charged by journals to authors for submitting/publishing their research papers/article.

The APC/Submission (Publication) Fee of the Journal is Base Fee, $1900, OA Price $6000

Call for paper : The Journal invites original research contributions for consideration of publication in Molecular Cancer Therapeutics journal.

Journal seeking submissions in the broad areas of Medicine that align with journal's focus on Medicine.

for details about call for paper please visit to the official website of the journal to check the details about call for papers.

Publishing in Molecular Cancer Therapeutics involves the following steps:

• Research: Conduct high-quality, impactful research in the field of Medicine.
• Familiarize Yourself: Read and understand the aims and scope of Molecular Cancer Therapeutics to ensure your work aligns with their focus.
• Manuscript Preparation: Prepare your manuscript according to the Molecular Cancer Therapeutics guidelines, including formatting, length, and referencing style.
• Submission: Submit your manuscript through the journal's online submission system.

• Journal Website
• PubMed
• Scopus
• SCImago